ARTICLE | Clinical News

Biosimilar teriparatide regulatory update

November 18, 2016 6:31 PM UTC

EMA's CHMP recommended approval of Terrosa/Movymia, a biosimilar of osteoporosis drug Forsteo teriparatide from Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.). The biosimilar is under review to treat osteoporosis in postmenopausal women and in men at increased risk of fracture and osteoporosis associated with sustained systemic glucocorticoid therapy in men and women at increased risk of fracture. Forsteo is a human parathyroid hormone (PTH) fragment. Following patent expiration of Forsteo, Gedeon Richter will market the product as Terrosa and Stada Arzneimittel AG (Xetra:SAZ, Bad Vilbel, Germany) will launch the product as Movymia...